Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate AI-driven drug discovery platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...
IEEE

Cloth-Changing Person Re-Identification Based on the Backtracking Mechanism

Abstract: Person re-identification has been extensively studied and has made significant progress in recent years. However, traditional person re-identification methods mainly rely on clothing-related ...
IEEE

Performance Improvements Through Advanced PV Backtracking on Uneven Terrain

Abstract: The climatic sensitivity of new terrain-aware backtracking algorithms is evaluated across 800 locations in the continental USA on a representative synthetic rolling terrain. We find that a ...

Recursion jumps as J.P. Morgan upgrades on lead program

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the company's lead drug. Read more here.
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Benzinga.com

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...